In conclusion, histone modifier genes indicate clinical progression of PTCL - NOS and may represent a group of actionable biomarkers of this disease subtype. (haematologica.org)
Lower plasma ApoA1 levels were associated with an increased risk of clinical progression in APOE ɛ 4 carriers with SCD (HR 5.0 (1.3 — 18.9)-RRB-. (content.iospress.com)